Despite recent successes with targeted and immunotherapies in cutaneous melanoma, data on Co-M treated with similar therapies (anti-BRAF/anti-MEK/anti-PDL1) are promising but limited, often stemming from a single patient or small case series with inoperable or advanced disease prior to surgery [34,35,36,37,38]. Here, BRAF is linked to cutaneous melanoma.